Peptide beacons: a new design for polypeptide-based optical biosensors.

Bioconjug Chem

Department of Chemistry and Biochemistry, University of California, Santa Barbara, Santa Barbara, California 93106, USA.

Published: August 2007

Both epitope mapping and other in vitro selection techniques produce short polypeptides that tightly and specifically bind to any of a wide range of macromolecular targets. Here, we demonstrate a potentially general means of converting such polypeptides into optical biosensors. The sensing architecture we have developed, termed peptide beacons, is based on the observation that, whereas short peptides are almost invariably unfolded and highly dynamic, they become rigid when complexed to a macromolecular target. Using this effect to segregate a long-lived fluorophore from an electron transfer based, contact quencher (both covalently attached to the peptide), we have produced a robust optical sensor for anti-HIV antibodies. The binding-induced segregation of the fluorophore-quencher pair produces a 6-fold increase in sensor emission, thus allowing us to readily detect as low as approximately 250 pM of the target antibody. Because the sensor is based on binding-induced folding and a visible-light fluorophore, it is sufficiently selective to work directly in complex, contaminant-ridden samples such as saliva and blood.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528055PMC
http://dx.doi.org/10.1021/bc060319uDOI Listing

Publication Analysis

Top Keywords

peptide beacons
8
optical biosensors
8
beacons design
4
design polypeptide-based
4
polypeptide-based optical
4
biosensors epitope
4
epitope mapping
4
mapping vitro
4
vitro selection
4
selection techniques
4

Similar Publications

Recent developments in treatments for both forms of advanced age-related macular degeneration (AMD) have led to the approval of multiple agents and modalities within the last few years. Five new medications for both neovascular AMD (nAMD) and geographic atrophy (GA) secondary to nonexudative AMD (neAMD) have been FDA-approved within the last 5 years, along with a new device designed for sustained drug delivery for nAMD. In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F.

View Article and Find Full Text PDF

Purpose: Intravitreal delivery of therapeutic transgenes to the retina via engineered viral vectors can provide sustained local concentrations of therapeutic proteins and thus potentially reduce the treatment burden and improve long-term vision outcomes for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy.

Methods: We performed directed evolution in nonhuman primates (NHP) to invent an adeno-associated viral (AAV) variant (R100) with the capacity to cross vitreoretinal barriers and transduce all regions and layers of the retina following intravitreal injection. We then engineered 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C.

View Article and Find Full Text PDF

Infections caused by () have emerged as a global public health concern because of high pathogenicity of this bacterium. Monoclonal antibodies (mAbs) have a lower likelihood of promoting drug resistance and offer targeted treatment, thereby reducing potential adverse effects; however, the therapeutic potential of mAbs targeting i has not been fully characterized. In this study, mAbs against the outer membrane proteins (OMPs) of were isolated in a high-throughput manner.

View Article and Find Full Text PDF

The increasing prevalence of obesity and type 2 diabetes mellitus has resulted in a significant challenge to public health throughout the globe. It required the development of novel therapeutic approaches. Retatrutide is a groundbreaking triple agonist that targets glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1.

View Article and Find Full Text PDF

The effects of fulvic acids and low-level laser therapy on orthodontic retention in rats.

BMC Oral Health

September 2024

Department of Stomatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.

Article Synopsis
  • - The study aimed to address orthodontic challenges by examining the effects of natural fulvic acids (FAs) and low-level laser therapy (LLLT) on the retention of teeth in rats after movement.
  • - Results showed that while FAs alone did not significantly impact relapse rates, both LLLT and a combination of FAs with LLLT effectively reduced relapse rates and improved periodontal health compared to a control group.
  • - Additionally, all treatment groups increased the expression of BMP-2, a protein important for bone and tissue health, but only LLLT and the combination treatment showed significantly greater improvements compared to FAs alone.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!